All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Epigenetic modifier mutations
Epigenetic modifier mutations
Epigenetic modifiers alter the chromatin structure through posttranslational modifications, such as DNA methylation, thereby changing the accessibility to DNA and gene expression. Mutations in epigenetic regulators, such as DNMT3A, IDH1, IDH2, TET2, ASXL1, EZH2, and MLL/KMT2A, are a key part of leukemogenesis. These mutations are believed to promote clonal outgrowth but require subsequent mutational events to initiate leukemic transformation.